Catalyst Pharmaceuticals News and Activities
Presence
Catalyst Pharmaceuticals develops and sells prescription medicines for rare neurological and seizure-related conditions. Its products and support services serve patients, doctors, hospitals, and specialty pharmacies in the United States.
Catalyst Pharmaceuticals products and services overview:
- Rare disease drugs
- Neurology treatments
- Seizure medicines
- Prescription therapies
- Patient support services
Revenue: ~$500 million
Employees: 190
Headquarters: Coral Gables, United States (USA)
Catalyst Pharmaceuticals is one of the...
Catalyst Pharmaceuticals is a company listed under the stock ticker CPRX (US).
Acquisition, funding and merger involving Catalyst Pharmaceuticals.
- Angelini Pharma has announced the acquisition of Catalyst Pharmaceuticals (posted on May 4 2026).
Executives
View the org chart displaying its 27 main executives
Most searched biographies at Catalyst Pharmaceuticals
- Richard Daly, Director and Chief Executive Officer
- David Tierney, Director
- Patrick McEnany, Non-Executive Chairman of the Board
Create your alert
to follow the executive moves at Catalyst Pharmaceuticals.
Pharmaceuticals
Catalyst Pharmaceuticals has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
- Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Catalyst Pharmaceuticals
- Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference : Catalyst Pharmaceutical
- Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update : Catalyst Pharmaceutical
- Press Releases : Catalyst Pharmaceutical
- Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals : Catalyst Pharmaceutical
- Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE® : Catalyst Pharmaceutical
- Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo : Catalyst Pharmaceutical
- Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023 : Catalyst Pharmaceutical
- Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference : Catalyst Pharmaceutical
- Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE® : Catalyst Pharmaceutical
- Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer : Catalyst Pharmaceutical
- View more press releases Close
Social media about Catalyst Pharmaceuticals
- Catalyst Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Catalyst Pharmaceuticals on LinkedIn, X (Twitter) & YouTube
